BioPharmaJournal
Progenity Inc. (NASDAQ:PROG) Announces Expansion Of COVID-19 RT-PCR Test In The…
TG Therapeutics Inc. (NASDAQ:TGTX) Presents Triple Combination Data At 62nd American…
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Provides Updates Of Its 2020 Achievements And…
Heron Therapeutics Inc. (NASDAQ:HRTX) Resubmits HTC-011 New Drug Application To The…
Incyte (NASDAQ:INCY) Releases Phase 3 Jakafi® In Combination with SOC Study…
Bitcoin Stocks for the Win (SQ, RIOT, ISWH, HVBTF)
The Contrarian Opportunity in Sports Stocks (CHDN, DKNG, BTDG, DKS)
Menlo Therapeutics Inc (NASDAQ:MNLO) Reports Positive Data From Phase 2 Clinical…
OSI Systems, Inc. (NASDAQ:OSIS) Bags $5 Million Order For The Supply…
TrialSpark Collaborates with resTORbio, Inc. (NASDAQ:TORC) and Integrates the Project Covalence…
Tauriga Sciences Inc (OTCMKTS:TAUG) Could React on New Aegea Rapid Test…
Micro and Macro Tailwinds Converge for KULR
ISWH and the Rebirth of the Crypto Cycle
Home Biotech Axovant Gene Therapies Ltd (NASDAQ:AXGT) Enters Manufacturing And Supply Agreement With Oxford...
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Enters Manufacturing And Supply Agreement With Oxford BioMedica For The Supply Of Clinical Trial Material For Phase 2 And 3 Trials
Gavins Felicity
A subsidiary of Axovant Gene Therapies Ltd (NASDAQ:AXGT) entered a 3-year pact with Oxford BioMedica Plc (OTCMKTS:OXBDF) for the manufacture and supply of GMP batches. Axovant will use Oxford's material to support the development of a clinical-stage gene therapy product – AXO-Lenti-PD for the treatment of patients with moderate to severe Parkinson's disease.
Completes dosing in the second cohort
Phase 2 SUNRISE-PD clinical trial is underway at Axovant using AXO-Lenti-PD. The company completed the dosing of patients in the second cohort and expects 6-month efficacy and safety data in Q4 2020. Oxford will use its GMP manufacturing facilities for the manufacture of AXO-Lenti-PD. It will also use its OXB GMP facilities to ensure continued supply for the trial.
CEO of Axovant, Pavan Cheruvu, said the accord allows both the companies to advance AXO-Lenti-PD development jointly. The partnership with Oxford helps the company scale up the supply of clinical material to support its Phase 2 and Phase 3 clinical trials and commercialize it. It is another milestone for the company in its Parkinson's disease program and expects to enroll the first patient in a sham-controlled and randomized clinical study next year.
Pavan said the company achieved significant progress in its three clinical-stage GTDP (gene therapy development programs) in Q1 2021 in Parkinson's disease, Tay-Sachs/ Sandhoff diseases, and GM1 gangliosidosis. The company expects to announce the results of these programs by the end of this year.
In Q1 2021, Axovant enrolled Type II Juvenile patients for the low dose cohort of its AXO-AAV-GM1's dose-escalation clinical trial. The company will initiate Type 1 (Infantile) GM1 treatment by the end of this year. Pavan further said the company will issue an update on its three clinical-stage programs soon.
To align with its governance and corporate structure, Axovant will continue corporate transformation with the existing and upcoming business activities. As part of this measure, the company will add more independent directors on its board besides incorporating a change in the company's name by March 2021.
Axovant narrowed down its nets loss YoY to $8.6 million in Q1 2021. The company used $13.5 million for operational activities in Q1 2021. It holds cash equivalents and cash of $55.5 million by the end of Q1 2021.
Axovant Gene Therapies Ltd
Axovant Gene Therapies Ltd (NASDAQ:AXGT)
NASDAQ:AXGT
OTCMKTS:OXBDF
Oxford BioMedica Plc
Oxford BioMedica Plc (OTCMKTS:OXBDF)
Previous articleAllena Pharmaceuticals Inc (NASDAQ:ALNA) Expands Clinical Trial Sites Of URIROX-2: Initiates Phase 1 Clinical Trial Of ALLN-346: Raises $22.7 Million
Next articleAerpio Pharmaceuticals Inc (NASDAQ:ARPO) Commences Phase 2 Clinical Study To Assess Razuprotafib Potential To Cure Ocular Hypertension In Patients
I am a senior writer at BP Journal. I am tasked with creating content that provides information about and analyzes financial markets, the economy and all things money-related. I have Master's in Business Administration with major in Finance.
Progenity Inc. (NASDAQ:PROG) Announces Expansion Of COVID-19 RT-PCR Test In The US
TG Therapeutics Inc. (NASDAQ:TGTX) Presents Triple Combination Data At 62nd American Society of Haematology Conference
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Provides Updates Of Its 2020 Achievements And Future Strategy
© BioPharma Journal 2020
.td-post-views{ display: none !important; }